Status:

COMPLETED

Neurobiology of Sensory Phenomena in Obsessive-Compulsive Disorder

Lead Sponsor:

NYU Langone Health

Conditions:

Obsessive Compulsive Disorder

Eligibility:

All Genders

18-60 years

Brief Summary

The Research Domain Criteria (RDoC) approach seeks to address the neurobiological mechanisms of sensory symptoms in patients with obsessive-compulsive disorder (OCD) by investigating dimensional compo...

Detailed Description

This project investigates the neurobiological mechanisms of sensory symptoms in patients with obsessive-compulsive disorder (OCD) and their siblings using task-based fMRI, resting-state functional con...

Eligibility Criteria

Inclusion

  • Fluent (speaking and writing) in English
  • Additional criteria for healthy controls (HC):
  • Lifetime absence of major Axis I diagnosis according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria
  • Not taking psychotropic medications
  • No first-degree biological relatives with OCD
  • Additional criteria for siblings (SIB):
  • First-degree biological sibling of a person with OCD
  • Additional criteria for OCD patients:
  • Diagnosis of OCD according to DSM-5 criteria.

Exclusion

  • Current moderate or high suicidality as assessed through the Mini International Neuropsychiatric Interview (MINI) 7.0.2 suicidality module
  • MRI contraindications such as claustrophobia, ferrous implants, braces, or pacemakers
  • Major neurological illness (e.g., self-reported history of organic mental syndromes, head trauma, migraines, seizures, other Central Nervous System (CNS) disease, or other significant medical illness that would make participation unsafe or unfeasible)
  • Positive urine toxicology or pregnancy test
  • Any disability or health problem that prevents them from completing study procedures (e.g. back problems, severe carpal tunnel syndrome, impaired vision that is not corrected with glasses or contact lenses, etc.).
  • Present diagnosis of alcohol use disorder or substance use disorder (moderate or severe)
  • Present or previous diagnosis of psychosis, bipolar disorder, or major developmental disorder (autism spectrum disorder, intellectual developmental disorder) based on DSM-5 criteria.

Key Trial Info

Start Date :

May 5 2018

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 24 2024

Estimated Enrollment :

308 Patients enrolled

Trial Details

Trial ID

NCT03451409

Start Date

May 5 2018

End Date

January 24 2024

Last Update

July 26 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

New York University School of Medicine

New York, New York, United States, 10016